Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

HOERSHOLM, Denmark and SAN DIEGO, April 26 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

High cholesterol is a major risk factor for coronary heart disease, heart attack and stroke. According to the World Health Organization, high cholesterol is estimated to cause 18% of strokes and 56% of heart disease, globally and amounts to approximately 4.4 million deaths and 40.4 million disability-adjusted life years(1).

Santaris Pharma A/S presented preclinical data on SPC5001 last month at the PCSK9 Conference "From gene to therapeutics" in Nantes, France where many top pharmaceutical companies gathered to discuss efforts to develop therapies aimed at inhibiting the important new target PCSK9, a protein involved in regulating LDL (low-density lipoprotein) or "bad" cholesterol in the blood.

Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels or the "good" cholesterol in the blood(2). The preclinical data suggest that SPC5001 has the potential to provide patients with a new treatment opti
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... “Never say, ‘I cannot do ... Department of Physics, advises young women pursuing careers ... SPIE Women in Optics 18-month planner ... ask questions.” , In the annual planner, women ... ranging from university professor and laboratory researcher to ...
(Date:12/17/2014)... Beach, CA (PRWEB) December 17, 2014 ... Inc. to provide a larger packaged waste water treatment ... in King Abdullah Economic City (KAEC). Two years ago ... EMAAR’s Jeddah Gate Development, serving two residential towers with ... capacity is over a quarter million gallons per day ...
(Date:12/17/2014)... Menlo Park, CA (PRWEB) December 17, 2014 ... Inc. announces today that it has entered into ... Daniels Midland Company (ADM) to apply DNA2.0’s proprietary ... industrial enzyme engineering process. , “We are extremely ... our ProteinGPS engineering platform. This proprietary bioengineering ...
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... (NYSE: TMO ) announced that it will host ... starting at 9:00 a.m. (EDT), at The,Grand Hyatt New ... City., The meeting will feature presentations by members ... an in-depth company,overview as well as expectations for future ...
... CITY, May 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, will announce ... market open on Wednesday, May 7,2008. The Company ... discuss these,results later that same day at 4:00 ...
... Raffaele Hospital in Milan and Northeast Georgia Medical Center in ... Gainesville, ... ... ST. LOUIS, May 1 Stereotaxis, Inc. (Nasdaq:,STXS) announced today the first ever bi-directional ...
Cached Biology Technology:Thermo Fisher Scientific to Host Analyst Meeting 2Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network 2Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network 3Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network 4
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... , University of Iowa biologist Daniel Eberl and his colleagues have ... to the battery in your car. And if that isn,t ... by studying a similar auditory system in fruit fliesand by making ... the mechanism of hearing resembles a battery, you need to know ...
... -- The ability to focus and switch tasks readily ... following brain concussions suffered by high school athletes, according ... Research team members, in an interview, said the discovery ... than current practices dictate to lower the risk of ...
... Researchers have discovered a new compound that restores ... aureus (MRSA), an otherwise dangerous bacterial infection. The ... cells but which is essential to bacterial survival. ... of Illinois and the University of California, San Diego, ...
Cached Biology News:UI researcher learns mechanism of hearing is similar to car battery 2Cognitive deficits from concussions still present after 2 months 2Cognitive deficits from concussions still present after 2 months 3New compound overcomes drug-resistant Staph infection in mice 2New compound overcomes drug-resistant Staph infection in mice 3
... Processing mini Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
... 1 g. High quality kits ... preparation that give consistent and ... and tissues.Clean up samples from ... Accurately quantitate protein for first-dimension ...
GOAT ANTI CARICA PAPAYA PAPAIN...
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
Biology Products: